- Home
- NCA vs AQST Comparison
NCA vs AQST Comparison
Compare NCA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- AQST
- Stock Information
- Founded
- NCA 1987
- AQST 2004
- Country
- NCA United States
- AQST United States
- Employees
- NCA N/A
- AQST N/A
- Industry
- NCA Investment Managers
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- NCA Finance
- AQST Health Care
- Exchange
- NCA Nasdaq
- AQST Nasdaq
- Market Cap
- NCA N/A
- AQST 254.1M
- IPO Year
- NCA N/A
- AQST 2018
- Fundamental
- Price
- NCA $8.64
- AQST $2.76
- Analyst Decision
- NCA
- AQST Strong Buy
- Analyst Count
- NCA 0
- AQST 5
- Target Price
- NCA N/A
- AQST $11.40
- AVG Volume (30 Days)
- NCA 59.6K
- AQST 984.2K
- Earning Date
- NCA 01-01-0001
- AQST 05-12-2025
- Dividend Yield
- NCA 3.92%
- AQST N/A
- EPS Growth
- NCA N/A
- AQST N/A
- EPS
- NCA N/A
- AQST N/A
- Revenue
- NCA N/A
- AQST $57,561,000.00
- Revenue This Year
- NCA N/A
- AQST N/A
- Revenue Next Year
- NCA N/A
- AQST $39.51
- P/E Ratio
- NCA N/A
- AQST N/A
- Revenue Growth
- NCA N/A
- AQST 13.79
- 52 Week Low
- NCA $7.77
- AQST $2.20
- 52 Week High
- NCA $9.12
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- NCA 62.72
- AQST 48.51
- Support Level
- NCA $8.42
- AQST $2.65
- Resistance Level
- NCA $8.58
- AQST $3.05
- Average True Range (ATR)
- NCA 0.09
- AQST 0.16
- MACD
- NCA 0.03
- AQST 0.00
- Stochastic Oscillator
- NCA 100.00
- AQST 50.51
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.